Key result
Infarct size was 29% larger in spontaneously hypertensive stroke-prone rats than controls, and pretreatment with erythropoietin limited infarct size in controls but not in hypertensive rats.
Why the study?
Does erythropoietin pretreatment reduce infarct size in spontaneously hypertensive stroke-prone rats compared to normotensive controls?
Does erythropoietin pretreatment reduce infarct size in spontaneously hypertensive stroke-prone rats compared to normotensive controls?
Hypertensive hypertrophied hearts show increased vulnerability to infarction and resistance to erythropoietin-induced cardioprotection due to reactive oxygen species-mediated mitochondrial dysfunction.
Hypertension may blunt erythropoietin cardioprotection; hypothesis-generating for mitochondrial mechanisms before human translation.
The objective of this study was to examine the hypothesis that hypertensive hypertrophy is vulnerable to infarction and defective in cytoprotective mechanisms by modification of intracellular signaling and mitochondrial proteins. Myocardial infarction was induced by 20-minute coronary occlusion/reperfusion in spontaneously hypertensive stroke-prone rats (SHR-SPs) and their controls (Wistar-Kyoto rats [WKYs]). Infarct size expressed as a percentage of area-at-risk was larger by 29% in SHR-SPs than in WKYs. Pretreatment with erythropoietin (EPO) significantly limited infarct size in WKYs but not in SHR-SPs. Ca(2+) retention capacity of mitochondria, an index of the threshold for opening of the mitochondrial permeability transition pore, on reperfusion was reduced in SHR-SPs compared with that in WKYs. Suppression of reactive oxygen species by N-(2-mercaptopropionyl)-glycine increased Ca(2+) retention capacity after reperfusion and limited infarct size in SHR-SPs to levels in WKYs. EPO induced phosphorylation of Akt, extracellular signal-related kinase, and glycogen synthase kinase-3β in the myocardium in both WKYs and SHR-SPs. EPO enhanced interaction of phospho-glycogen synthase kinase-3β and adenine nucleotide translocase on reperfusion in WKYs, although such an effect of EPO was not detected in SHR-SPs. The results suggest that enhanced opening of mitochondrial permeability transition pores by reactive oxygen species and modification of the signal downstream of phospho-glycogen synthase kinase-3β in the mitochondria underlie the increased vulnerability to infarction and the lack of anti-infarct tolerance by EPO, respectively, in hypertensive hypertrophied hearts.
No takes yet. Share an insight, caveat, or question.
Yano et al. (2010) studied Hypertensive hypertrophy and myocardial infarction. Erythropoietin (EPO) vs. No EPO / Wistar-Kyoto controls was evaluated on Infarct size expressed as a percentage of area-at-risk. Infarct size was 29% larger in spontaneously hypertensive stroke-prone rats than controls, and pretreatment with erythropoietin limited infarct size in controls but not in hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: